Global Blood Therapeutics, Inc. (GBT)
$68.49
Rating:
Recommendation:
Neutral
| Symbol | GBT |
|---|---|
| Price | $68.49 |
| Beta | 0.463 |
| Volume Avg. | - |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 21.65-73.02 |
| 1y Target Est | - |
| DCF Unlevered | GBT DCF -> | |
|---|---|---|
| DCF Levered | GBT LDCF -> | |
| ROE | -129.89% | Strong Sell |
| ROA | -18.83% | Sell |
| Operating Margin | - | |
| Debt / Equity | 556.26% | Strong Buy |
| P/E | -14.08 | Strong Sell |
| P/B | 37.96 | Strong Buy |
Latest GBT news
About
Download (Excel)Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.